Speakers - Sachs Associates

More documents

Recommendations

Info

Pharma Licensing Groups represented at the Forum Pharma Licensing Groups www.amgen.co.uk www.astellas.eu www.biogenidec.co.uk www.helsinn.com www.ipsen.com www.jnj.com www.menarini-biotech.com www.merck.com www.merckserono.co.uk/en/index.html www.norgine.com www.novartisoncology.com www.novartisvaccines.com www.pierre-fabre.com www.roche.com www.sanofi.com www.nycomed.com WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
<strong>Speakers</strong> Alexey Eliseev, Managing Director, Maxwell Biotech Alexey received his PhD in Chemistry from Moscow State University and MBA from the Sloan School of Management at the Massachusetts Institute of Technology. His career includes over 17 years of experience in academia, biotechnology industry and venture capital. Dr. Eliseev has been working in the United States and Europe since 1992. Following three years of postdoctoral research in Germany as an Alexander von Humboldt Fellow and in the US, he joined faculty at the department of Medicinal Chemistry, University at Buffalo in 1995 where he was awarded tenure in 2000. In 1999 he co-founded the company Therascope (later Alantos Pharmaceuticals) with a number of prominent founders including French Nobel Laureate Jean-Marie Lehn. The company used a novel drug discovery technology developed in several academic labs, including Eliseev’s group in Buffalo. He joined the company in 2000 and later became Chief Technology Officer of Alantos and President of its US division. Alantos was acquired by Amgen in 2007 for $300 million. Over the recent years Alexey was involved in starting several biotech companies as a scientist and entrepreneur, including AC Immune (Switzerland) and Boston BioCom (US). Alexey has been working with the Russian-based Maxwell Biotech Venture Fund as its Managing Director since 2009. He is responsible for international activity of the Fund and has managed numerous deals with portfolio companies in the US and Europe. Allan Marchington, Partner, Apposite Capital Allan is a founder and Partner at Apposite Capital a London based healthcare investor. Allan was formerly at Abingworth management and prior to this was a member of Millennium Pharmaceuticals management team as an Senior Vice President with responsibility for technology Investments. He also served as Chairman of Millennium Pharmaceuticals in Europe. Allan joined Millennium following their acquisition in July 2000 of Cambridge Discovery Chemistry, where he was CEO and founder. Allan began his career as a medicinal chemist at Pfizer Central Research. Allan is a Board member of the BioIndustry Association, Ambit Biosciences Inc., Ambrx Inc., Anaphore Inc., and Convergence Pharmaceuticals Ltd. Dr Andreas Caduff, CEO, BioVoition AG Andreas was born in 1971 and is a Swiss citizen. He held various positions in the pharmaceutical and medical device industry. In his previous position he was serving as CTO of Solianis Monitoring AG, a company focusing on noninvasive glucose monitoring. At Solianis, he orchestrated the overall technology and product development, experimental/clinical study strategies, regulatory considerations, external technical communication and interaction with the industrial/scientific community, regulatory bodies as well as the investor’s community. He is an expert in physiological monitoring techniques and involved physiological/metabolic processes, combining the expertise in various fields relevant to the development, industrialisation and commercialisation of such technologies. Dr. Caduff is a frequent invited speaker at industrial and scientific conferences and meetings on physiological monitoring, mobile Health and related subjects. He has innovated numerous patents and co-authored several dozen scientific publications in peer reviewed journals. He holds a BSc degree in Chemistry from the University of Applied Science, Winterthur, Switzerland, an MSc degree in Biotechnology and a Ph.D. in Biophysics from the University of Teesside, UK and the Hebrew University of Jerusalem, Israel. Anne Altmeyer, Executive Director Business Development & Licensing, Novartis Oncology Anne is a Vice President in Business Development and Licensing in the Oncology Business Unit at Novartis, USA. Her responsibilities are to in-license or acquire Oncology assets that can further strengthen the Novartis Oncology portfolio. In this role, she identifies, evaluates, and negotiates transactions for oncology opportunities. She also manages several ongoing alliances. Anne has over 15 years of experience in the Pharmaceutical Industry working in positions of increasing responsibilities in Research, Development, and Business Development and Licensing. Anne joined the Oncology Project Management group of Novartis in 2004 as a Project Leader. There she led numerous multidisciplinary Project Teams through the generation and implementation of strategies for various compounds in development and on the market. Before joining Novartis, Anne worked as a Project Manager at Merck & Co. for close to 4 years and as a Visiting Research Scientist for 2 years. Anne received her Ph.D. in Molecular Immunology from Strasbourg University, France. She then performed a postdoctoral fellowship at New York University School of Medicine, USA, and subsequently became a Research Associate at Cornell University Medical College, New York, USA. In addition to her scientific training, Anne also received a Master in Business Administration and a Master in Public Health from the University of Medicine and Dentistry of New Jersey/Rutgers, USA. t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2: B I O T E C H I N E U R O P E I N V
Page 3: Events Diary For regular updates, s
Page 7 and 8: Speakers Blake M. Paterson, Co-Foun
Page 9 and 10: Speakers David Slack, Head of Corpo
Page 11 and 12: Speakers Frank Grams, VP, Head Alli
Page 13 and 14: Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16: Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18: Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20: Speakers Paul Higham, Managing Dire
Page 21 and 22: Speakers Richard Goodfellow, CEO, S
Page 23 and 24: Speakers Søren Moller, Managing In
Page 25 and 26: CONTACT Robert F Burns, PhD Chief E
Page 27 and 28: CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30: CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32: CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34: CONTACT Carina Schmidt Chief Execut
Page 35 and 36: CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38: CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56:
CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58:
CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60:
CONTACT Malcolm Weir Chief Executiv
Page 61 and 62:
CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64:
CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66:
CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68:
CONTACT Maaike Vogelezang Managemen
Page 69 and 70:
CONTACT Tom Johnston Chief Executiv
Page 71 and 72:
CONTACTS Aaron Powers President Dav
Page 73 and 74:
CONTACTS General and Media Contact
Page 75 and 76:
CONTACTS Martin Welschof Chief Exec
Page 77 and 78:
CONTACTS Carlos Buesa Chief Executi
Page 79 and 80:
CONTACTS Nick McCooke Chief Executi
Page 81 and 82:
CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84:
CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86:
CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88:
ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90:
CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92:
CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94:
CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96:
CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98:
CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100:
CONTACTS Piers Morgan Chief Financi
Page 101 and 102:
CONTACT Jakob Knudsen Chief Executi
Page 103 and 104:
CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106:
Supporting Organisations Citigate D
Page 107 and 108:
Supporting Organisations Life Scien
Page 109 and 110:
Supporting Organisations Swiss Biot
Page 111 and 112:
Supporting Organisations Torreya Pa
Page 113:
B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

Create successful ePaper yourself

Delete template?

Save as template?